Reversibility of tacrolimus-induced posttransplant diabetes: an illustrative case and review of the literature
| Autor: | Ron Shapiro, Velma P. Scantlebury, T.R. Hakala, T. E. Starzl, Hans Albin Gritsch, Jerry McCauley, Simmons Rl, C.A Vivas, John J. Fung, Mark L. Jordan |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Graft Rejection
medicine.medical_specialty Population Gastroenterology Tacrolimus Article Internal medicine Diabetes mellitus Diabetes Mellitus Humans Transplantation Homologous Medicine education Kidney transplantation Transplantation education.field_of_study Kidney Graft rejection business.industry Incidence (epidemiology) Middle Aged medicine.disease Kidney Transplantation Surgery surgical procedures operative medicine.anatomical_structure Renal transplant Female business Immunosuppressive Agents |
| Zdroj: | Transplantation Proceedings. 29:2737-2738 |
| ISSN: | 0041-1345 |
| DOI: | 10.1016/s0041-1345(97)00576-9 |
| Popis: | Tacrolimus is a potent immunosuppressive agent. It has been reported to have superior immunosuppressive efficacy when compared with the standard formulation of cyclosporine (CyA),1 based on its ability to rescue patients with failing allografts under CyA-based therapy,2,3 lower rejection rates when used as a primary immunosuppressive agent,4,5 and longer projected half-life.6 However, there have been reports of an increased incidence of posttransplant diabetes (PTDM) under tacrolimus-based therapy.4,5 We have reported on the reversibility of tacrolimus-induced PTDM in our own renal transplant patients.7,8 In this article, we present an illustrative case demonstrating the reversibility of PTDM and review both the published and unpublished literature. The data suggest that the initial incidence of PTDM in the renal transplant population may be higher under tacrolimus than under CyA-based therapy, but the final incidence is comparable.9–11 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect